Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus.

Trial Profile

Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Acronyms MOA
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Mar 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Jul 2009 Actual initiation date changed from Jan 2009 to Jun 2009 as reported by ClinicalTrials.gov.
    • 10 Jul 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top